Previous 10 | Next 10 |
2024-01-30 08:20:13 ET More on Palatin Tech Palatin rises as it completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171M Seeking Alpha’s Quant Rating on Palatin Tech Historical earnings data for Palatin Tech Read the full article on Seeki...
2024-01-11 13:38:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips After four long years of volatility and economic uncertainty, there finally appears to be light at the end of the tunnel heading into 2024. As rates start coming down and monetary policy loosen...
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 PR Newswire Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study Data Base Lock 2H January 2024 Topline Data Readout Expected Early 1Q Calendar Year 2024 Ulcerative...
Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder (HSDD) Vyleesi ® has experienced 8 Consecutive Quarters of Double-Digit Prescription Growth Acquisition Adds Another...
2023-12-29 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, ...
2023-12-20 08:29:09 ET More on Palatin Tech Palatin Tech Q1 2024 Earnings Preview Palatin falls on common stock and warrants offering Seeking Alpha’s Quant Rating on Palatin Tech For further details see: Palatin rises as it completes sale of Vylees...
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million PR Newswire Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin's focus is solely on its development and clinical pipeline ...
2023-12-18 16:19:23 ET More on Palatin Tech Palatin falls on common stock and warrants offering Seeking Alpha’s Quant Rating on Palatin Tech For further details see: Palatin receives notice of acceptance of listing standards compliance plan from NYSE American
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American PR Newswire CRANBURY, N.J. , Dec. 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class med...
2023-12-04 17:10:25 ET More on Palatin Tech Seeking Alpha’s Quant Rating on Palatin Tech For further details see: Palatin Technologies files to sell 2.48M shares of common stock for holders
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing fi...
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) PR Newswire In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5...
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end...